The AAIC 2026 news means a blood biomarker test helped primary-care doctors diagnose Alzheimer's far more accurately in patients with memory symptoms. A blood biomarker test measures Alzheimer's-related proteins in blood to support diagnosis, not replace a clinical exam.
Lund University neurologist Sebastian Palmqvist presented the real-world Swedish study in London. It focused on adults with mild cognitive impairment, meaning early memory or thinking changes, or dementia. For patients, the practical question is how a result would change next steps.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How much did accuracy improve?
- What did the test measure?
- Why was ruling out more useful?
- What are the limits right now?
- What should you ask your doctor?
How much did accuracy improve?
The Alzheimer's Association reports primary-care accuracy rose from 65% before results to 93% after, near specialists' 94% accuracy details. The report found no significant difference between groups after disclosure.
Clinical Lab Products reports the study enrolled 1,310 patients with mild cognitive impairment or dementia study enrollment. The group included 383 patients in primary care and 927 in specialty care. One hundred sixty-five physicians made diagnoses before and after seeing results.
What did the test measure?
MIMS coverage of abstract 6718 says physicians used C2N Diagnostics' PrecivityAD2 test. It measured two blood signals: plasma %p-tau217 and Aβ42/40 ratio. Both reflect Alzheimer's-related protein changes.
Results were reported as negative, intermediate, or positive using two cutoffs. Negative suggests Alzheimer's pathology is unlikely. Positive suggests it is more likely, while intermediate needs clinical judgment and often more testing.
Why was ruling out more useful?
The Alzheimer's Association highlighted the test as most helpful in primary care for ruling out Alzheimer's rather than ruling it in. A negative result can redirect attention to other causes of memory change. Those causes include medication effects, depression, sleep apnea, and other brain disorders.
After reviewing results, primary-care doctors changed the diagnosis in about 30% of patients, according to the Alzheimer's Association. They also changed planned examinations and care in more than half of cases. That shift can reduce unneeded referrals and speed the right follow-up.
What are the limits right now?
The findings were a conference presentation in a Swedish cohort, not a peer-reviewed guideline change. The Alzheimer's Association overview notes they do not establish stand-alone primary-care screening. This is especially true for people without symptoms.
The U.S. Food and Drug Administration says its cleared blood tests, including Lumipulse G pTau217/β-Amyloid 1-42, are cleared only for adults 55 and older with cognitive symptoms as part of a full workup FDA clearance notice. They are not cleared for general screening. A workup still means history, cognitive testing, exam, and often brain imaging or specialist input.
What should you ask your doctor?
Bring symptoms, timing, medications, and family observations to the visit. Ask whether a blood test would alter diagnosis, referrals, or treatment. A useful test should answer a decision, not add uncertainty.
- What is your current diagnosis and how certain is it?
- Would a blood result change tests, referrals, or medicines?
- What does a negative, intermediate, or positive result mean for me?
- What follow-up is planned if the result is unclear?
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Primary Care Patients Can Avoid Overreading the Headline
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Primary Care Patients Can Avoid Overreading the Headline
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: How Primary Care Patients Can Avoid Overreading the Headline
